Related Experiment Video
Updated: Jul 10, 2026
A RAPID Method for Blood Processing to Increase the Yield of Plasma Peptide Levels in Human Blood
Published on: April 28, 2016
Co-administration of SR141716 with peptide YY3-36 or oxyntomodulin has additive effects on food intake in mice
N E White1, W S Dhillo, Y-L Liu
1Department of Metabolic Medicine, Faculty of Medicine, Imperial College London, Hammersmith Hospital, London, UK.
Background:
SR141716 has been shown to significantly inhibit food intake and reduce body weight by antagonizing CB(1) receptors. The gut hormones peptide YY(3-36) (PYY(3-36)) and oxyntomodulin (OXM) inhibit food intake through Y(2) and Glucagon-Like-Peptide (GLP)-1 receptors respectively.
Objective:
To determine the effects of co-administration of SR141716 with either PYY(3-36) or OXM in mice on food intake.
Methods:
Mice (n = 14 per group) were fasted for 16 h prior to study days and given two intraperitoneal injections: study 1, vehicle-saline, SR141716-saline, vehicle-PYY3-36 or SR141716-PYY3-36; study 2: vehicle-saline, SR141716-saline, vehicle-OXM or SR141716-OXM. Food was returned and measured following injections.
Results:
Co-administration of SR141716-PYY(3-36) or SR141716-OXM showed greater inhibition in food intake when compared with administration of SR141716, PYY(3-36) or OXM alone.
Conclusion:
Our data show that SR141716 in combination with PYY(3-36) or OXM reduces food intake additively in mice.
Related Concept Videos
01:30Regulation of Food Intake
01:24Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
01:16Gastric Emptying